NASDAQ:ARAV - Aravive Stock Price, Forecast & News

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Aravive Inc (NASDAQ:ARAV) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.04. View Aravive's Earnings History.

Aravive is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Aravive.

5 brokerages have issued 1-year target prices for Aravive's stock. Their forecasts range from $25.00 to $31.00. On average, they anticipate Aravive's share price to reach $28.50 in the next year. This suggests a possible upside of 147.8% from the stock's current price. View Analyst Price Targets for Aravive.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aravive.

Press coverage about ARAV stock has trended negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aravive earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Aravive.

Aravive saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 82,500 shares, a decrease of 35.8% from the December 15th total of 128,500 shares. Based on an average trading volume of 489,700 shares, the short-interest ratio is presently 0.2 days. Approximately 1.2% of the company's stock are short sold. View Aravive's Current Options Chain.

Some companies that are related to Aravive include Cytokinetics (CYTK), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Flexion Therapeutics (FLXN), Cara Therapeutics (CARA), DiaMedica Therapeutics (DMCAF), Processa Pharmaceuticals (PCSA), Retrophin (RTRX), Emisphere Technologies (EMIS), ImmunoGen (IMGN), Omeros (OMER), Axovant Sciences (AXON), Vectura Group (VEGPF), TherapeuticsMD (TXMD) and AC Immune (ACIU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Aurinia Pharmaceuticals (AUPH), Agile Therapeutics (AGRX), Amarin (AMRN), Global Blood Therapeutics (GBT), Aerie Pharmaceuticals (AERI), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), DURECT (DRRX), Foamix Pharmaceuticals (FOMX) and Intra-Cellular Therapies (ITCI).

Aravive's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.69%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju. View Institutional Ownership Trends for Aravive.

ARAV stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Aravive.

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARAV stock can currently be purchased for approximately $11.50.

Aravive has a market capitalization of $168.48 million and generates $1.37 million in revenue each year. The company earns $-76,330,000.00 in net income (profit) each year or ($10.64) on an earnings per share basis. Aravive employs 14 workers across the globe.View Additional Information About Aravive.

The official website for Aravive is http://www.aravive.com/.

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]